Effect of Paromomycin Sulfate on Endotoxemia in Patients with Cirrhosis
We evaluated, in a randomized double-blind trial, the efficacy of oral paromomycin sulfate administration in the prevention of endotoxemia in 24 cirrhotic patients with endotoxemia. Renal function was evaluated by glomerular-filtration rate and renal plasma flow at the beginning and at the end of th...
Gespeichert in:
Veröffentlicht in: | Journal of clinical gastroenterology 1982-06, Vol.4 (3), p.263-268 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 268 |
---|---|
container_issue | 3 |
container_start_page | 263 |
container_title | Journal of clinical gastroenterology |
container_volume | 4 |
creator | Tarao, Kazuo Moroi, Tamaki Hirabayashi, Yoshiki Ikeuchi, Takao Endo, Osamu Takamura, Yutaro |
description | We evaluated, in a randomized double-blind trial, the efficacy of oral paromomycin sulfate administration in the prevention of endotoxemia in 24 cirrhotic patients with endotoxemia. Renal function was evaluated by glomerular-filtration rate and renal plasma flow at the beginning and at the end of the study period. After the administration of paromomycin sulfate, 2 g/day for 4 weeks, endotoxemia disappeared in 10 out of 13 (76.9%) cirrhotic patients with endotoxemia, whereas it became negative in only 3 of the 11 (27.3%) treated with placebo, the difference being significant (P < 0.05).With regard to correlation of endotoxemia with renal impairment, endogenous creatinine clearance and p-ami-nohippurate clearance were significantly improved (P < 0.02) in those patients whose endotoxemia disappeared on paromomycin sulfate administration. We did not find significant improvement, however, neither in liver function or in blood coagulation tests in the same patients. Paromomycin sulfate seems to be effective in the prevention of endotoxemia and the associated renal impairment in cirrhosis in man. |
doi_str_mv | 10.1097/00004836-198206000-00013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_74051553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>74051553</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3553-70acfb38cde7fbad62ff01727aae6f8574a8437ad255bbcdb1bd1c231eaa1d683</originalsourceid><addsrcrecordid>eNp1kVFLwzAUhYMoc05_gpAn36pJ0zbto4w5hYED9Tmk6Q2Nts1MUub-vdHNvXkhXMI5957wBSFMyS0lFb8jsbKSFQmtypQU8ZbEQ9kJmtKcVUlKGD1FU0KrNCG8Iufowvv36OCM0QmacFIVVUGmaLnQGlTAVuO1dLa3_U6ZAb-MnZYBsB3wYmhssF_QG4mjspbBwBA83prQ4rlxrrXe-Et0pmXn4erQZ-jtYfE6f0xWz8un-f0qUSzPWcKJVLpmpWqA61o2Rap1fFTKpYRClznPZJkxLps0z-taNTWtG6pSRkFK2hQlm6Gb_d6Ns58j-CB64xV0nRzAjl7wjOQ0JkVjuTcqZ713oMXGmV66naBE_DAUfwzFkaH4ZRhHrw8ZY91Dcxw8QIt6tte3tgvg_Ec3bsGJFmQXWvHf17Bvjhp8vg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>74051553</pqid></control><display><type>article</type><title>Effect of Paromomycin Sulfate on Endotoxemia in Patients with Cirrhosis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Tarao, Kazuo ; Moroi, Tamaki ; Hirabayashi, Yoshiki ; Ikeuchi, Takao ; Endo, Osamu ; Takamura, Yutaro</creator><creatorcontrib>Tarao, Kazuo ; Moroi, Tamaki ; Hirabayashi, Yoshiki ; Ikeuchi, Takao ; Endo, Osamu ; Takamura, Yutaro</creatorcontrib><description>We evaluated, in a randomized double-blind trial, the efficacy of oral paromomycin sulfate administration in the prevention of endotoxemia in 24 cirrhotic patients with endotoxemia. Renal function was evaluated by glomerular-filtration rate and renal plasma flow at the beginning and at the end of the study period. After the administration of paromomycin sulfate, 2 g/day for 4 weeks, endotoxemia disappeared in 10 out of 13 (76.9%) cirrhotic patients with endotoxemia, whereas it became negative in only 3 of the 11 (27.3%) treated with placebo, the difference being significant (P < 0.05).With regard to correlation of endotoxemia with renal impairment, endogenous creatinine clearance and p-ami-nohippurate clearance were significantly improved (P < 0.02) in those patients whose endotoxemia disappeared on paromomycin sulfate administration. We did not find significant improvement, however, neither in liver function or in blood coagulation tests in the same patients. Paromomycin sulfate seems to be effective in the prevention of endotoxemia and the associated renal impairment in cirrhosis in man.</description><identifier>ISSN: 0192-0790</identifier><identifier>EISSN: 1539-2031</identifier><identifier>DOI: 10.1097/00004836-198206000-00013</identifier><identifier>PMID: 7096960</identifier><language>eng</language><publisher>United States: Lippincott-Raven Publishers</publisher><subject>Acute Kidney Injury - etiology ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Liver Cirrhosis - complications ; Liver Function Tests ; Male ; Middle Aged ; Paromomycin - therapeutic use ; Random Allocation ; Toxemia - drug therapy</subject><ispartof>Journal of clinical gastroenterology, 1982-06, Vol.4 (3), p.263-268</ispartof><rights>Lippincott-Raven Publishers.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3553-70acfb38cde7fbad62ff01727aae6f8574a8437ad255bbcdb1bd1c231eaa1d683</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7096960$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tarao, Kazuo</creatorcontrib><creatorcontrib>Moroi, Tamaki</creatorcontrib><creatorcontrib>Hirabayashi, Yoshiki</creatorcontrib><creatorcontrib>Ikeuchi, Takao</creatorcontrib><creatorcontrib>Endo, Osamu</creatorcontrib><creatorcontrib>Takamura, Yutaro</creatorcontrib><title>Effect of Paromomycin Sulfate on Endotoxemia in Patients with Cirrhosis</title><title>Journal of clinical gastroenterology</title><addtitle>J Clin Gastroenterol</addtitle><description>We evaluated, in a randomized double-blind trial, the efficacy of oral paromomycin sulfate administration in the prevention of endotoxemia in 24 cirrhotic patients with endotoxemia. Renal function was evaluated by glomerular-filtration rate and renal plasma flow at the beginning and at the end of the study period. After the administration of paromomycin sulfate, 2 g/day for 4 weeks, endotoxemia disappeared in 10 out of 13 (76.9%) cirrhotic patients with endotoxemia, whereas it became negative in only 3 of the 11 (27.3%) treated with placebo, the difference being significant (P < 0.05).With regard to correlation of endotoxemia with renal impairment, endogenous creatinine clearance and p-ami-nohippurate clearance were significantly improved (P < 0.02) in those patients whose endotoxemia disappeared on paromomycin sulfate administration. We did not find significant improvement, however, neither in liver function or in blood coagulation tests in the same patients. Paromomycin sulfate seems to be effective in the prevention of endotoxemia and the associated renal impairment in cirrhosis in man.</description><subject>Acute Kidney Injury - etiology</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Function Tests</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paromomycin - therapeutic use</subject><subject>Random Allocation</subject><subject>Toxemia - drug therapy</subject><issn>0192-0790</issn><issn>1539-2031</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kVFLwzAUhYMoc05_gpAn36pJ0zbto4w5hYED9Tmk6Q2Nts1MUub-vdHNvXkhXMI5957wBSFMyS0lFb8jsbKSFQmtypQU8ZbEQ9kJmtKcVUlKGD1FU0KrNCG8Iufowvv36OCM0QmacFIVVUGmaLnQGlTAVuO1dLa3_U6ZAb-MnZYBsB3wYmhssF_QG4mjspbBwBA83prQ4rlxrrXe-Et0pmXn4erQZ-jtYfE6f0xWz8un-f0qUSzPWcKJVLpmpWqA61o2Rap1fFTKpYRClznPZJkxLps0z-taNTWtG6pSRkFK2hQlm6Gb_d6Ns58j-CB64xV0nRzAjl7wjOQ0JkVjuTcqZ713oMXGmV66naBE_DAUfwzFkaH4ZRhHrw8ZY91Dcxw8QIt6tte3tgvg_Ec3bsGJFmQXWvHf17Bvjhp8vg</recordid><startdate>198206</startdate><enddate>198206</enddate><creator>Tarao, Kazuo</creator><creator>Moroi, Tamaki</creator><creator>Hirabayashi, Yoshiki</creator><creator>Ikeuchi, Takao</creator><creator>Endo, Osamu</creator><creator>Takamura, Yutaro</creator><general>Lippincott-Raven Publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>8BM</scope></search><sort><creationdate>198206</creationdate><title>Effect of Paromomycin Sulfate on Endotoxemia in Patients with Cirrhosis</title><author>Tarao, Kazuo ; Moroi, Tamaki ; Hirabayashi, Yoshiki ; Ikeuchi, Takao ; Endo, Osamu ; Takamura, Yutaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3553-70acfb38cde7fbad62ff01727aae6f8574a8437ad255bbcdb1bd1c231eaa1d683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Acute Kidney Injury - etiology</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Function Tests</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paromomycin - therapeutic use</topic><topic>Random Allocation</topic><topic>Toxemia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tarao, Kazuo</creatorcontrib><creatorcontrib>Moroi, Tamaki</creatorcontrib><creatorcontrib>Hirabayashi, Yoshiki</creatorcontrib><creatorcontrib>Ikeuchi, Takao</creatorcontrib><creatorcontrib>Endo, Osamu</creatorcontrib><creatorcontrib>Takamura, Yutaro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>ComDisDome</collection><jtitle>Journal of clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tarao, Kazuo</au><au>Moroi, Tamaki</au><au>Hirabayashi, Yoshiki</au><au>Ikeuchi, Takao</au><au>Endo, Osamu</au><au>Takamura, Yutaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Paromomycin Sulfate on Endotoxemia in Patients with Cirrhosis</atitle><jtitle>Journal of clinical gastroenterology</jtitle><addtitle>J Clin Gastroenterol</addtitle><date>1982-06</date><risdate>1982</risdate><volume>4</volume><issue>3</issue><spage>263</spage><epage>268</epage><pages>263-268</pages><issn>0192-0790</issn><eissn>1539-2031</eissn><abstract>We evaluated, in a randomized double-blind trial, the efficacy of oral paromomycin sulfate administration in the prevention of endotoxemia in 24 cirrhotic patients with endotoxemia. Renal function was evaluated by glomerular-filtration rate and renal plasma flow at the beginning and at the end of the study period. After the administration of paromomycin sulfate, 2 g/day for 4 weeks, endotoxemia disappeared in 10 out of 13 (76.9%) cirrhotic patients with endotoxemia, whereas it became negative in only 3 of the 11 (27.3%) treated with placebo, the difference being significant (P < 0.05).With regard to correlation of endotoxemia with renal impairment, endogenous creatinine clearance and p-ami-nohippurate clearance were significantly improved (P < 0.02) in those patients whose endotoxemia disappeared on paromomycin sulfate administration. We did not find significant improvement, however, neither in liver function or in blood coagulation tests in the same patients. Paromomycin sulfate seems to be effective in the prevention of endotoxemia and the associated renal impairment in cirrhosis in man.</abstract><cop>United States</cop><pub>Lippincott-Raven Publishers</pub><pmid>7096960</pmid><doi>10.1097/00004836-198206000-00013</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0192-0790 |
ispartof | Journal of clinical gastroenterology, 1982-06, Vol.4 (3), p.263-268 |
issn | 0192-0790 1539-2031 |
language | eng |
recordid | cdi_proquest_miscellaneous_74051553 |
source | MEDLINE; Journals@Ovid Complete |
subjects | Acute Kidney Injury - etiology Double-Blind Method Drug Administration Schedule Female Humans Liver Cirrhosis - complications Liver Function Tests Male Middle Aged Paromomycin - therapeutic use Random Allocation Toxemia - drug therapy |
title | Effect of Paromomycin Sulfate on Endotoxemia in Patients with Cirrhosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A11%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Paromomycin%20Sulfate%20on%20Endotoxemia%20in%20Patients%20with%20Cirrhosis&rft.jtitle=Journal%20of%20clinical%20gastroenterology&rft.au=Tarao,%20Kazuo&rft.date=1982-06&rft.volume=4&rft.issue=3&rft.spage=263&rft.epage=268&rft.pages=263-268&rft.issn=0192-0790&rft.eissn=1539-2031&rft_id=info:doi/10.1097/00004836-198206000-00013&rft_dat=%3Cproquest_cross%3E74051553%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=74051553&rft_id=info:pmid/7096960&rfr_iscdi=true |